Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O75462
UPID:
CRLF1_HUMAN
Alternative names:
Cytokine-like factor 1; ZcytoR5
Alternative UPACC:
O75462; Q9UHH5
Background:
Cytokine receptor-like factor 1, also known as Cytokine-like factor 1 or ZcytoR5, plays a pivotal role in neuronal development and immune system regulation. This protein, identified by the accession number O75462, forms a heterodimeric neurotropic cytokine in complex with CLCF1, underscoring its importance in neurobiology.
Therapeutic significance:
Cytokine receptor-like factor 1 is linked to Crisponi/Cold-induced sweating syndrome 1, a disorder manifesting in neonatal orofacial weakness, hyperhidrosis, and other abnormalities. Understanding the role of Cytokine receptor-like factor 1 could open doors to potential therapeutic strategies for this autosomal recessive disorder.